欢迎访问中国烧伤创疡杂志网站！

胶体酒石酸铋胶囊联合美沙拉嗪治疗溃疡性结肠炎疗效分析
Analysis of Clinical Efficacy of Colloidal Bismuth Tartrate Capsules Combined with Mesalazine in the Treatment of Ulcerative Colitis

冯双双,周新.胶体酒石酸铋胶囊联合美沙拉嗪治疗溃疡性结肠炎疗效分析[J].中国烧伤创疡杂志,2022,(6):445~448.

DOI：

英文关键词:Colloidal Bismuth Tartrate Capsules Mesalazine Ulcerative colitis Inflammatory response Oxidative stress

基金项目:

作者	单位
冯双双	471000 河南洛阳, 河南科技大学第一附属医院药剂科
周新	471000 河南洛阳, 河南科技大学第一附属医院消化内科

摘要点击次数: 1553

全文下载次数: 4247

中文摘要:

【摘要】目的探讨胶体酒石酸铋胶囊联合美沙拉嗪治疗溃疡性结肠炎 (UC) 的临床疗效。方法选取2019 年1月至2021年1 月河南科技大学第一附属医院收治的 86 例 UC 患者作为研究对象, 按照随机数表法将其随机分为观察组 (43 例) 和对照组 (43 例), 观察组患者采用胶体酒石酸铋胶囊联合美沙拉嗪肠溶片治疗, 对照组患者单纯采用美沙拉嗪肠溶片治疗, 对比观察两组患者超敏C反应蛋白(hs-CRP)、一氧化氮 (NO)、脂质过氧化物(LPO)水平变化情况, 临床疗效以及不良反应发生情况。结果治疗4周后,观察组患者 hs-CRP、NO及LPO水平均明显低于对照组 ( t = 4.863? 5.819? 3.705, P 均 < 0.001); 治疗4周后, 观察组患者总有效率为 95.35% , 明显高于对照组患者的总有效率 81.40% ( χ 2 = 4.074, P = 0.044); 治疗期间, 观察组患者不良反应发生率为 6.98%, 与对照组患者的不良反应发生率 11.63% 无明显差异(χ 2 = 0.551, P = 0.458)。结论胶体酒石酸铋胶囊联合美沙拉嗪可有效缓解 UC 患者局部炎症反应及氧化应激反应, 提高治疗效果, 且安全性较高, 值得临床推广应用。

英文摘要:

【Abstract】 Objective To study the clinical efficacy of Colloidal Bismuth Tartrate Capsules combined with Mesalazine in the treatment of ulcerative colitis (UC). Methods 86 patients with UC, admitted into The First Affiliated Hospital of Henan University of Science and Technology between January 2019 and January 2021, were enrolled and divided into study group (n = 43) and control group (n = 43) by using the random number table. Patients in study group were treated with Colloidal Bismuth Tartrate Capsules combined with Mesalazine Enteric?coated Tablets, while patients in control group were treated with Mesalazine Enteric?coated Tablets alone. Changes of hypersensitive C-reactive protein ( hs-CRP), nitric oxide (NO) and lipid peroxide (LPO), clinical efficacy and occurrence of adverse reactions were compared between the two groups. Results After 4 weeks of treatment, the levels of hs?CRP, NO and LPO of patients were obviously lower in study group than control group (t = 4.863, 5.819 and 3.705, all P < 0.001), and the total effective rate in study group was 95.35% , significantly higher than the corresponding 81.40% in control group ( χ 2 = 4.074, P = 0.044). During the course of treatment, the incidence of adverse reactions was 6.98% in study group, which showed no statistically significant difference compared with 11.63% in control group ( χ 2 = 0.551, P = 0.458). Conclusion The combined application of Colloidal Bismuth Tartrate Capsules and Mesalazine in the treatment of UC can effectively relieve patients’ local inflammatory responses and oxidative stress, and enhance therapeutic effects. Moreover, it is safe to use.